"Johnson & Johnson's Q1 Earnings: Mixed Results and Talc Issues Loom"

Johnson & Johnson reported mixed Q1 earnings, with revenue slightly below expectations but beating on adjusted earnings per share. The company's pharmaceutical sector, particularly in oncology and immunology, performed well, while its MedTech division showed growth potential. Johnson & Johnson also narrowed its full-year guidance, citing competition in the pharmaceutical sector and focusing on areas of growth such as cardiology.